F C Beikert1, M Augustin, M A Radtke. 1. CeDeF - Competenzzentrum Dermatologische Forschung, IVDP - Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland. florian.beikert@uke.de
Abstract
BACKGROUND: With a prevalence of 0.71%, psoriasis represents one of the most frequent dermatoses in childhood. PATIENTS AND METHODS: Eight children with severe psoriasis who failed to respond to other therapy received a weight- adapted treatment with etanercept (0.8 mg/kg body) administered subcutaneously once weekly after latent tuberculosis had been excluded. Follow-up visits were at week 4 and 12, subsequently every 12 weeks. RESULTS: Mean age at the start of treatment was 11.8 (range 7-16), six patients were boys. Within three months, six patients reached Psoriasis Area and Severity Index (PASI) reduction of 75%. Two patients stopped use at week 12 because of ineffectiveness. Apart from local side reactions and minor infections, no adverse events were observed. CONCLUSION: In our case series, etanercept proved to be an efficient drug in juvenile psoriasis without serious adverse events. However, patient registries and further randomized, double-blinded control studies are crucial to evaluate long-term efficacy and safety of etanercept.
BACKGROUND: With a prevalence of 0.71%, psoriasis represents one of the most frequent dermatoses in childhood. PATIENTS AND METHODS: Eight children with severe psoriasis who failed to respond to other therapy received a weight- adapted treatment with etanercept (0.8 mg/kg body) administered subcutaneously once weekly after latent tuberculosis had been excluded. Follow-up visits were at week 4 and 12, subsequently every 12 weeks. RESULTS: Mean age at the start of treatment was 11.8 (range 7-16), six patients were boys. Within three months, six patients reached Psoriasis Area and Severity Index (PASI) reduction of 75%. Two patients stopped use at week 12 because of ineffectiveness. Apart from local side reactions and minor infections, no adverse events were observed. CONCLUSION: In our case series, etanercept proved to be an efficient drug in juvenile psoriasis without serious adverse events. However, patient registries and further randomized, double-blinded control studies are crucial to evaluate long-term efficacy and safety of etanercept.
Authors: Richard G Langley; Amy S Paller; Adelaide A Hebert; Kara Creamer; Haoling H Weng; Angelika Jahreis; Denise Globe; Vaishali Patel; Seth J Orlow Journal: J Am Acad Dermatol Date: 2010-07-08 Impact factor: 11.527
Authors: D J Lovell; E H Giannini; A Reiff; G D Cawkwell; E D Silverman; J J Nocton; L D Stein; A Gedalia; N T Ilowite; C A Wallace; J Whitmore; B K Finck Journal: N Engl J Med Date: 2000-03-16 Impact factor: 91.245
Authors: Amy S Paller; Elaine C Siegfried; Richard G Langley; Alice B Gottlieb; David Pariser; Ian Landells; Adelaide A Hebert; Lawrence F Eichenfield; Vaishali Patel; Kara Creamer; Angelika Jahreis Journal: N Engl J Med Date: 2008-01-17 Impact factor: 91.245
Authors: Joel R Rosh; Trudy Lerer; James Markowitz; Sri R Goli; Petar Mamula; Joshua D Noe; Marian D Pfefferkorn; Kathleen T Kelleher; Anne M Griffiths; Subra Kugathasan; David Keljo; Maria Oliva-Hemker; Wallace Crandall; Ryan S Carvalho; David R Mack; Jeffrey S Hyams Journal: Am J Gastroenterol Date: 2009-09-01 Impact factor: 10.864